Literature DB >> 31401583

Using an Impella device to reverse refractory cardiac arrest and enable efficient coronary revascularisation.

Nicolas Persico1,2, Christophe Guervilly2,3, Baptiste Verhamme1, Laurent Bonello4.   

Abstract

We report the case of a 54-year-old man who suffered from refractory cardiac arrest secondary to acute myocardial infarction. As veno-arterial extracorporeal membrane oxygenation was unavailable, mechanical chest compression was performed and an Impella device was used that immediately delivered at 3.2 l/min flow to reach the optimal mean arterial pressure. Within 1 min, return of spontaneous circulation was achieved and a 40% left ventricular ejection fraction was measured on echography. Then, the right coronary artery could be revascularised. Despite 62 min low flow, the patient was discharged home on day 19 without neurological sequelae. During refractory cardiac arrest, the European Resuscitation Guidelines indicate that veno-arterial extracorporeal membrane oxygenation should be considered as rescue therapy. Other mechanical circulatory supports such as an Impella device (left ventricular assist device propelling blood in the ascending aorta) can be a promising treatment in select patients; however, insufficient data in humans are available. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  adult intensive care; interventional cardiology; resuscitation

Mesh:

Year:  2019        PMID: 31401583      PMCID: PMC6700542          DOI: 10.1136/bcr-2019-230654

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  4 in total

1.  European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support.

Authors:  Jasmeet Soar; Jerry P Nolan; Bernd W Böttiger; Gavin D Perkins; Carsten Lott; Pierre Carli; Tommaso Pellis; Claudio Sandroni; Markus B Skrifvars; Gary B Smith; Kjetil Sunde; Charles D Deakin
Journal:  Resuscitation       Date:  2015-10       Impact factor: 5.262

2.  A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study.

Authors:  William W O'Neill; Neal S Kleiman; Jeffrey Moses; Jose P S Henriques; Simon Dixon; Joseph Massaro; Igor Palacios; Brijeshwar Maini; Suresh Mulukutla; Vladimír Dzavík; Jeffrey Popma; Pamela S Douglas; Magnus Ohman
Journal:  Circulation       Date:  2012-08-30       Impact factor: 29.690

3.  The Impella CP device for acute mechanical circulatory support in refractory cardiac arrest.

Authors:  Henrik Vase; Steffen Christensen; Aage Christiansen; Christian Juhl Therkelsen; Evald Høj Christiansen; Hans Eiskjær; Steen Hvidtfeldt Poulsen
Journal:  Resuscitation       Date:  2016-10-14       Impact factor: 5.262

Review 4.  Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials.

Authors:  Jin M Cheng; Corstiaan A den Uil; Sanne E Hoeks; Martin van der Ent; Lucia S D Jewbali; Ron T van Domburg; Patrick W Serruys
Journal:  Eur Heart J       Date:  2009-07-18       Impact factor: 29.983

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.